方舟花
Lv1
30 积分
2022-07-07 加入
-
A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
10天前
已完结
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
10天前
已完结
-
DisagreementsBetweenFDAanditsOncologicDrugsAdvisoryCommittee(ODAC)
11天前
已完结
-
In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?
1个月前
已完结
-
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
1个月前
已完结
-
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
3个月前
已完结
-
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts
3个月前
已完结
-
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
4个月前
已完结
-
Classic Hodgkin lymphoma
4个月前
已完结